REVERAGEN BIOPHARMA, INC.
US UEI NQA4J3L3E1Z4 · SME
11public awards
$11.2Mtotal public funding
2020-09-01latest award
State aid awards (11)
| Date | Amount | Type | Programme | Granted by |
|---|---|---|---|---|
| 2020-09-01 | $3.4M | Grant | Commercialization Readiness Pilot (CRP) to maximize vamorolone interna | Department of Health and Human Services |
| 2018-09-01 | $3.1M | Grant | Pivotal trial of vamorolone in Duchenne muscular dystrophy | Department of Health and Human Services |
| 2018-07-01 | $225k | Grant | Building an evidentiary case for circulating GHBP as a biomarker for d | Department of Health and Human Services |
| 2018-06-05 | $225k | Grant | Definition of pharmacodynamic biomarkers for juvenile dermatomyositis | Department of Health and Human Services |
| 2018-06-01 | $178k | Grant | Establishing a biomarker framework for feasibility studies of vamorolo | Department of Health and Human Services |
| 2016-04-01 | $254k | Grant | Effectiveness of VBP15, a dissociative steroidal analogue, on chronic | Department of Health and Human Services |
| 2016-02-15 | $3.0M | Grant | Phase IIa study of VBP for Duchenne muscular dystrophy | Department of Health and Human Services |
| 2015-09-01 | $225k | Grant | Effectiveness of VBP15, a dissociative steroidal analogue, on inflamma | Department of Health and Human Services |
| 2014-01-01 | $225k | Grant | Effect of VBP15, a dissociative steroidal analogue, on intestinal epit | Department of Health and Human Services |
| 2014-01-01 | $225k | Grant | Evaluation of VBP15 a dissociative steroidal analogue on pain and infl | Department of Health and Human Services |
| 2010-01-01 | $179k | Grant | Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in L | Department of Health and Human Services |
Want an alert when companies like this one get funded in your sector? Pro waitlist →